Katalog der Deutschen Nationalbibliothek

Go to:

Catalogue (Beta)

Knowledge Web

Person
Person

Person

Peter Andreas Fasching (1975-)

Arzt

Name

Peter Andreas Fasching

Time

1975- (Date of birth and death)

Place

Deutschland

Gender

männlich

Academic degree

Prof. Dr. med.

Profession

Arzt (characteristic profession)

Variant

Peter A. Fasching
Peter Fasching

Related

Universitätsklinikum Erlangen
Gynäkologie (Thema)
Krebsforschung (Thema)

Record type

Person

GND-Identifier

129068780

Record ID

129068780

Involved in

show all

Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer

Publisher Correction: Understanding the genetic complexity of puberty timing across the allele frequency spectrum

Understanding the genetic complexity of puberty timing across the allele frequency spectrum

Correlation of RANK and RANKL with mammographic density in primary breast cancer patients

Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study

Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer

Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry

CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs

Discussion of ABC7 Consensus and German Recommendations

Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study

Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study

Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024

ABC7 Consensus: Assessment by a German Group of Experts

Attrition in the first three therapy lines in patients with advanced breast cancer in the German real-world PRAEGNANT registry

CDK4/6 inhibition – therapy sequences and the quest to find the best biomarkers – an overview of current programs = CDK4/6-Inhibition: Sequenztherapien und die Suche nach den besten Biomarkern – ein Überblick über die aktuellen Programme

Correction: Long-term follow-up and safety of patients after an upfront therapy with letrozole for early breast cancer in routine clinical care – the PreFace study = Erratum: Langfristige Nachbeobachtung und Sicherheit im klinischen Alltag bei Patientinnen nach Upfront-Therapie mit Letrozol zur Behandlung von Brustkrebs im Frühstadium – die PreFace-Studie

ESR1 Liquid Biopsy im metastasierten Mammakarzinom bei endokriner Resistenz

Long-term follow-up and safety of patients after an upfront therapy with letrozole for early breast cancer in routine clinical care – the preface study = Langfristige Nachbeobachtung und Sicherheit im klinischen Alltag bei Patientinnen nach Upfront-Therapie mit Letrozol zur Behandlung von Brustkrebs im Frühstadium – die PreFace-Studie

Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole

Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer

The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

Update breast cancer 2024 part 1 - expert opinion on advanced breast cancer

Update Mammakarzinom 2024 Teil 1 – Expertenmeinungen zu Brustkrebs in fortgeschrittenen Krankheitsstadien = Update breast cancer 2024 part 1 – expert opinion on advanced breast cancer

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

Prevalence and course of pregnancy symptoms using self-reported pregnancy app symptom tracker data

Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study

Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer

Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer

Chemotherapie-induzierte (febrile) Neutropenien : Prophylaxe, Behandlung und Status Quo in der Versorgung

Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare

Update breast cancer 2023 Part 1 – early stage breast cancer

Update breast cancer 2023 Part 1: early stage breast cancer

Update breast cancer 2023 part 2 – advanced-stage breast cancer

Update breast cancer 2023 part 2: advanced-stage breast cancer

Update breast cancer 2023 Part 3 – expert opinions of early stage breast cancer therapies

Update breast cancer 2023 part 3: expert opinions of early stage breast cancer therapies

Sex-specific association between prenatal androgenization (second-to-fourth digit length ratio) and frontal brain volumes in adolescents

Return of individual genomic research results within the PRAEGNANT multicenter registry study

The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C

Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT

Advanced Breast Cancer : AGO Recommendations 2022 – Focus on ABC6 Consensus

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022

Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference

ABC6 Consensus: Assessment by a Group of German Experts

Implementation of CDK4/6 inhibitors and its influence on the treatment landscape of advanced breast cancer patients – data from the real-world registry PRAEGNANT = Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium – Real-World-Daten aus dem PRAEGNANT-Register

Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics – a retrospective analysis of a real world registry

Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial

Real-world‐data of 12‐month adjunct SGLT2‐inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: improved HbA1c without DKA

Sex-specific association between prenatal androgenization (second-to-fourth digit length ratio) and frontal brain volumes in adolescents

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021

AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer : update 2021

Association of genomic variants at PAX8 and PBX2 with cervical cancer risk
Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

DNB portal